O TYM ODCINKU
Host: Jerome Lisk, MD, MBA, M.S., FAAN
Guest: Peter Whitehouse, MD, PhD
Guest: Peter Whitehouse, MD, PhD
The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.
Język angielski
Stany Zjednoczone
W TYM ODCINKU
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki NeuroFrontiers.
INNE ODCINKI W TYM PODCASCIE
Host: Brian P. McDonough, MD, FAAFP
Guest: Austin Larson, MD
Emerging research on thymidine kinase 2 deficiency (TK2d) provides new insights into its global genetic prevalence and variability across genetic ancestries. By combining clinical literature with large genomic databases, in…
Guest: Henry Kaminski, MD
Myasthenia gravis is an unpredictable condition, with symptoms and treatment responses that can vary widely from one patient to the next. Tune in to hear Dr. Henry Kaminski explain how to navigate this variability and make thoughtful, individualized treatment de…
Guest: Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
The role of cell-based therapies in multiple sclerosis (MS) is evolving, with immune system replacement via autologous stem cells, investigational mesenchymal repair strategies, and CAR T-cell approaches changing the treatment …
Host: Alexandria May, PharmD, BCPS
Guest: Kaitlin Batley, MD
Fatigue and muscle weakness may seem routine, but when do they signal an underlying condition like thymidine kinase 2 deficiency (TK2d)? To find out, Dr. Alexandria May speaks with Dr. Kaitlin Batley, Director of the Pediat…
Guest: Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
Cxplore how cell-based therapies are reshaping treatment strategies for multiple sclerosis (MS). Hear from Dr. Mark Freedman as he examines the scientific rationale behind emerging strategies. Dr. Freedman is a Profes…
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z ReachMD, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
